Oleyl alcohol
Based on 1 Customer Validation
Oleyl alcohol is an anti-tumor compound that inhibits tumor growth. Oleyl alcohol induces cytotoxicity, cell death and apoptosis. The intracellular accumulation of Oleyl alcohol correlates with its cytotoxicity against tumor cells. Oleyl alcohol forms enhancer-enriched fluid domains in stratum corneum lipids, increases the retention of diclofenac diethylamine in ex vivo human epidermis and dermis, and enhances the skin permeability of diclofenac diethylamine. Oleyl alcohol can be used in studies related to neuroblastoma.
For research use only. We do not sell to patients.
- Purity : 98.00%
- CAS No.: 143-28-2
- Formula: C18H36O
- Molecular Weight:268.48
-
Storage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vitro
Oleyl alcohol (5-50 μg/mL; 24 h) induces dose-dependent cytotoxicity in human neuroblastoma HTLA-230 cells, with PSO 2% 10:1 complexes showing the highest potency (IC50 = 10.1 μg/mL) and PSO 3% 3:1 complexes showing the lowest potency (IC50 = 41.6 μg/mL) after 24 h of treatment[1].
Oleyl alcohol (0.75% w/v; 24-48 h) increases DIC-DEA permeation through ex vivo human skin 2.8-fold after a single 24 h dose and 2.7-fold after four repeated doses over 48 h[3].
Oleyl alcohol (0.75% w/v; 24 h) does not adversely affect TEWL or electrical impedance of ex vivo human skin, with all barrier effects fully reversible within 24 h after sample removal[3].
Oleyl alcohol (0.75% w/v; 8-24 h) does not fluidize ex vivo human SC lipid chains after 8 or 24 h of application, forms fluid enhancer-rich domains in SC lipids after 24 h[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human neuroblastoma HTLA-230 cell line
-
Concentration:5-50 μg/mL
-
Incubation Time:24 h
-
Result:Induced dose-dependent cell death, with cytotoxicity correlating with release rates.
Reached an IC50 of 10.1 μg/mL for PSO 2% 10:1 complexes.
Reached an IC50 of 12.7 μg/mL for PSO 2% 5:1 complexes.
Reached an IC50 of 15.6 μg/mL for PSO 2% 3:1 complexes.
Reached an IC50 of 24.4 μg/mL for PSO 3% 10:1 complexes.
Reached an IC50 of 30.3 μg/mL for PSO 3% 5:1 complexes.
Reached an IC50 of 41.6 μg/mL for PSO 3% 3:1 complexes.
Showed no cytotoxicity for pure polymers at concentrations up to 500 μg/mL.
Chemical Information
-
CAS No. 143-28-2
-
Appearance Liquid (Density: 0.8489 g/cm³)
-
Molecular Weight 268.48
-
Formula C18H36O
-
Color Colorless to light yellow
-
SMILES
CCCCCCCC/C=C\CCCCCCCCO
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : ≥ 30 mg/mL (111.74 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Transepithelial/transendothelial electrical resistance assay
TEER measures electrical resistance across epithelial or endothelial monolayers cultured on permeable supports, and the readout reflects ionic conductance through the cell barrier, especially the paracellular pathway regulated by junctional integrity. TEER can be measured without destroying the monolayer and is commonly used before or during transport, permeability, barrier-disruption, and barrier-maturation experiments. TEER values are influenced by biological maturation and technical conditions; reported factors include temperature, medium formulation, passage number, electrode geometry, membrane properties, and junctional length during early monolayer maturation. Therefore, TEER should be interpreted with blank-insert subtraction, area normalization, repeated readings, and, when possible, orthogonal barrier readouts such as FITC-dextran flux or tight-junction staining.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Orienti I, et al. Enhancement of oleyl alcohol anti tumor activity through complexation in polyvinylalcohol amphiphilic derivatives. Drug delivery. 2007 Apr;14(4):209-17. [Content Brief]
[3]. Kováčik A, et al. Time-Dependent Differences in the Effects of Oleic Acid and Oleyl Alcohol on the Human Skin Barrier. Molecular pharmaceutics. 2023 Dec 04;20(12):6237-6245. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7247 mL | 18.6234 mL | 37.2467 mL | 93.1168 mL |
| 5 mM | 0.7449 mL | 3.7247 mL | 7.4493 mL | 18.6234 mL | |
| 10 mM | 0.3725 mL | 1.8623 mL | 3.7247 mL | 9.3117 mL | |
| 15 mM | 0.2483 mL | 1.2416 mL | 2.4831 mL | 6.2078 mL | |
| 20 mM | 0.1862 mL | 0.9312 mL | 1.8623 mL | 4.6558 mL | |
| 25 mM | 0.1490 mL | 0.7449 mL | 1.4899 mL | 3.7247 mL | |
| 30 mM | 0.1242 mL | 0.6208 mL | 1.2416 mL | 3.1039 mL | |
| 40 mM | 0.0931 mL | 0.4656 mL | 0.9312 mL | 2.3279 mL | |
| 50 mM | 0.0745 mL | 0.3725 mL | 0.7449 mL | 1.8623 mL | |
| 60 mM | 0.0621 mL | 0.3104 mL | 0.6208 mL | 1.5519 mL | |
| 80 mM | 0.0466 mL | 0.2328 mL | 0.4656 mL | 1.1640 mL | |
| 100 mM | 0.0372 mL | 0.1862 mL | 0.3725 mL | 0.9312 mL |